ANRO Stock Surges Following FDA Fast Track Designation for Schizophrenia Drug

Alto Neuroscience (ANRO) stock experienced a significant increase in premarket trading on October 3, 2025, following an important regulatory milestone. The company’s investigational drug for treating cognitive impairment associated with schizophrenia, ALTO-101, received Fast Track designation from the U.S. Food and Drug Administration (FDA). This designation expedites drug development for serious conditions with significant unmet medical needs. Analysts believe this advancement could lead to faster development timelines and potential regulatory advantages for ANRO’s program, sparking investor optimism about the company’s prospects.